InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Explore the complete record of transactions filed by Gamelin Erick. Director active across 1 company, notably Acrivon Therapeutics, Inc.. In total, 12 filings have been published. Split: 0 buy · 1 sell. Total volume traded: €694. Activity tracked since 14 November 2022. The latest transaction was disclosed on 18 August 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 条申报中的 12 条
Gamelin Erick is Chief Development Officer at Acrivon Therapeutics, Inc. He or she has 11 filings in total, and in the recent sample covering the period from 2022-11-16 to 2026-02-18, the transaction amounts are 0 EUR for buys and 0 EUR for sells, with tax withholding as the transaction nature.